Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Gilead Sciences

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases  Gilead SciencesGilead to acquire immunology biotech, offers lifeline to Galapagos  statnews.comGilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos  Fierce BiotechGilead Sciences buys autoimmune biotech Ouro Medicines for $2.2bn  Financial TimesGilead to buy biotech firm Ouro Medicines in over $2 billion deal  Reuters